Essential thrombocythemia and leukemic transformation.
Alkylating agents and 32P have been widely employed in the treatment of patients with essential thrombocythemia (ET). During a four-month period, we observed 3 cases of ET that had transformed into leukemia. Two patients had been treated with uracil mustard: One developed acute myelogenous leukemia 79 months after institution of therapy, and the other patient developed chronic myelomonocytic leukemia 24 months after the start of therapy. The third patient had been treated with busulfan, and ET evolved into myelofibrosis and eventually into acute undifferentiated leukemia with myelofibrosis. The patient who developed acute myelogenous leukemia was asymptomatic at the time of diagnosis of ET but was treated because his platelet count was greater than 1,000,000/mm3. He died 1 month after leukemic transformation, during induction chemotherapy. The other 2 patients presented with symptoms referable to their thrombocythemia. Review of the English literature revealed 12 other definite or probable cases of ET with leukemic transformation, all but 1 having been treated with alkylating agents and/or 32P. We propose that the natural history of ET may be similar to that of polycythemia vera, with evolution into leukemia being an unusual occurrence except in the setting of previous chemotherapy. Therefore, the current practice of treating asymptomatic patients with ET may not be justified, since administration of alkylating agents or 32P may increase the risk of subsequent development of leukemia.
Sedlacek
S M
SM
Curtis
J L
JL
Weintraub
J
J
Levin
J
J
D000328:Adult; D000368:Aged; D001853:Bone Marrow / Q000473:pathology; D002066:Busulfan / Q000009:adverse effects / Q000627:therapeutic use; D002471:Cell Transformation, Neoplastic / Q000503:physiopathology*; D006801:Humans; D007951:Leukemia, Myeloid / Q000209:etiology*; D015470:Leukemia, Myeloid, Acute / Q000209:etiology*; D008297:Male; D008875:Middle Aged; D013920:Thrombocythemia, Essential / Q000188:drug therapy / Q000503:physiopathology*; D014499:Uracil Mustard / Q000009:adverse effects / Q000627:therapeutic use
D002066:Busulfan; D014499:Uracil Mustard